Device and method for non-occlusive localized drug delivery

• US 5,985,307 A
• Filed: 12/02/1997
• Issued: 11/16/1999
• Est. Priority Date: 04/14/1993
• Status: Expired due to Fees

• Current Assignee: Emory University
• Original Assignee: Emory University
• Inventors: Markou, Christos, Hanson, Stephen R., Scott, Neal A., King, Spencer B. III
• Primary Examiner(s): Azpuru, Carlos A.
• Application Number:
  US08/982,537
• Time in Patent Office: 714 Days
• Field of Search: 424/423, 604/96, 604/101, 604/264, 604/280, 604/281
• US Class Current: 424/423
• CPC Class Codes: A61F 2/06 Blood vessels
• CPC Class Codes: A61F 2/064 with special features to facilitate anastomotic coupling anastomosis of natural blood vessels A61B17/11
• CPC Class Codes: A61F 2250/0003 having an inflatable pocket filled with fluid, e.g. liquid or gas
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61M 2025/0057 Catheters delivering medicament other than through a conventional lumen, e.g. porous walls or hydrogel coatings
• CPC Class Codes: A61M 2025/0063 having means, e.g. stylets, mandrils, rods or wires to reinforce or adjust temporarily the stiffness, column strength or pushability of catheters which are already inserted into the human body
• CPC Class Codes: A61M 2025/105 having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
• CPC Class Codes: A61M 2025/1072 having balloons with two or more compartments
• CPC Class Codes: A61M 2025/1081 having sheaths or the like for covering the balloon but not forming a permanent part of the balloon, e.g. retractable, dissolvable or tearable sheaths
• CPC Class Codes: A61M 25/00 Catheters; Hollow probes dilators A61M29/00; peritoneal catheters A61M1/285; tracheal tubes A61M16/04; for drainage A61M27/00; for uterus, vagina or rectum A61M31/00 ; for measuring or testing A61B; materials for catheters A61L29/00
• CPC Class Codes: A61M 25/0021 characterised by the form of the tubing A61M25/0054 takes precedence
• CPC Class Codes: A61M 25/0041 pre-formed, e.g. specially adapted to fit with the anatomy of body channels urethral catheters A61F2/04
• CPC Class Codes: A61M 25/0068 Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure
• CPC Class Codes: A61M 25/0074 Dynamic characteristics of the catheter tip, e.g. openable, closable, expandable or deformable
• CPC Class Codes: A61M 25/0082 Catheter tip comprising a tool
• CPC Class Codes: A61M 25/1002 characterised by balloon shape A61M25/1006, A61M25/1009 take precedence
• CPC Class Codes: A61M 31/00 Devices for introducing or retaining media, e.g. remedies, in cavities of the body A61M25/00 takes precedence ; introducing or retaining ophthalmic products into the ocular cavities A61F9/0008
• CPC Class Codes: A61M 37/00 Other apparatus for introducing media into the body for reproduction or fertilisation A61B17/425; apparatus for iontophoresis or cataphoresis A61N1/30; Percutany, i.e. introducing medicines into the body by diffusion through the skin salt baths A61H33/04

Abstract

A device for the local delivery of a substance into a natural tissue conduit in the mammalian body. The device provides a means for locally delivering a substance into the boundary layer of fluid flowing through the conduit without substantially disrupting the fluid flow therethrough. For example, an indwelling endovascular support device is provided for delivery of a substance locally to a targeted treatment area. Also provided are methods of locally delivering a substance into a natural tissue conduit in the mammalian body utilizing the device of the present invention.

Claims

1. A removable, expandable, non-occlusive endovascular support device adapted for providing prolonged localized delivery of a therapeutic agent to a preselected site within a blood vessel, comprising:

a. an inflatable, elongated, tubular-shaped balloon having a proximal end, a distal end and a central lumen therethrough, the tubular-shaped balloon having an inflation chamber defined by;

i. a medial exterior wall defining the central lumen;

ii. an opposite lateral exterior wall; and

iii. the opposed proximal and distal ends;

b. chamber inflation means in fluid connection with the inflation chamber; and

c. therapeutic agent delivery means located on a selected one of the medial exterior wall or the lateral exterior wall.

2. The device of claim 1, wherein the therapeutic agent delivery means comprises a selected one of the medial exterior wall or the lateral exterior wall defining a plurality of micro pores disposed therethrough.

3. The device of claim 2, wherein the micro pores are located in the lateral exterior wall and are juxtaposed to a luminal surface of the blood vessel such that a substance delivered therethrough directly contacts the luminal surface of the blood vessel.

4. The device of claim 2, wherein the micro pores are located in the medial exterior wall such that a substance delivered therethrough is delivered into the boundary layer of blood flowing through the blood vessel.

5. The device of claim 1, wherein the therapeutic agent delivery means comprises a selectively permeable membrane comprising at least a portion of a selected one of the medial or lateral exterior walls.

6. The device of claim 5, wherein the selectively permeable membrane is located in the lateral exterior wall and is juxtaposed to a luminal surface of the blood vessel such that a substance delivered therethrough directly contacts the luminal surface of the blood vessel.

7. The device of claim 5, wherein the selectively permeable membrane is located in the medial exterior wall such that a substance delivered therethrough is delivered into the boundary layer of blood flowing through the blood vessel.

8. The device of claim 5, wherein the selectively permeable membrane is comprised of a biocompatible material selected from the group consisting of a biodegradable polymer, a non-biodegradable polymer, a nylon and a porous metal alloy.

9. The device of claim 8, wherein the selectively permeable membrane is a non-biodegradable polymer selected from the group consisting of polytetrafluoroethylene, ethylene vinyl acetate, polyethylene, and polyethylene terephthalate.

10. The device of claim 1, wherein the predetermined site is the boundary layer of blood flowing through the blood vessel upstream of a target treatment area.

11. The device of claim 1, wherein the chamber inflation means comprises a low profile elongated inflation fluid supply tube in fluid communication with the proximal end of the inflation chamber.

12. The device of claim 1, further comprising support means for maintaining a predetermined shape of the balloon located within a selected one of the medial exterior wall, the lateral exterior wall or the inflation chamber.

13. The device of claim 12, wherein the support means further comprises a flexible support member of suitable stiffness so as to maintain the device in a predetermined shape upon deployment of the device at the preselected site.

14. The device of claim 13, wherein the flexible support member is comprised of a material selected from the group consisting of a metal, a plastic, a polymer, and a ceramic.

15. The device of claim 13, wherein the flexible support member extends radially within a selected one of medial exterior wall, the lateral exterior wall or the inflation chamber.

16. The device of claim 13, wherein the flexible support member extends longitudinally within a selected one of medial exterior wall, the lateral exterior wall or the inflation chamber.

17. The device of claim 1, wherein the medial exterior wall expands to a predetermined length and diameter in response to a preselected amount of an inflation fluid pressure applied to the inflation chamber by the chamber inflation means.

18. The device of claim 1, wherein the lateral exterior wall expands to a predetermined length and diameter in response to a preselected amount of inflation fluid pressure applied to the inflation chamber by the chamber inflation means.

19. The device of claim 1, wherein the inflation chamber inflates to a predetermined length along a longitudinal axis defined by the central lumen in response to a preselected amount of inflation fluid pressure applied to the inflation chamber by the chamber inflation means.

20. The device of claim 1, wherein the inflation chamber inflates to a predetermined diameter along a longitudinal axis defined by the central lumen in response to a preselected amount of inflation fluid pressure applied to the inflation chamber by the chamber inflation means.

21. The device of claim 20, wherein expansion of the inflation chamber to the predetermined length is controlled by a selected one of the medial exterior wall, the lateral exterior wall or a support means for maintaining a predetermined shape of the balloon located within a selected one of the material exterior wall, the lateral exterior wall or the inflation chamber.

22. The device of claim 1, wherein the medial exterior wall is of a predetermined length and a preselected elasticity.

23. The device of claim 1, wherein the lateral exterior wall is of a predetermined length and a preselected elasticity.

24. The device of claim 1, wherein the inflation chamber further comprises a plurality of longitudinally extending interconnected inflation cells disposed among a plurality of substantially non-expandable support members having a predetermined length and stiffness.

25. The device of claim 1, wherein the inflation chamber further comprises a plurality of radially extending interconnected inflation cells disposed among a plurality of substantially non-expandable support members having a predetermined length and stiffness.

26. The device of claim 1, wherein the therapeutic agent is disposed within a fluid supplied to the inflation chamber via the chamber inflation means.

27. The device of claim 1, wherein the therapeutic agent is a drug.

28. The device of claim 1, wherein the therapeutic agent is an anticoagulant selected from the group consisting of D-Phe-Pro-Arg chloromethyl ketone, an RGD peptide-containing compound, heparin, an antithrombin compound, a platelet receptor antagonist, an anti-thrombin antibody, an anti-platelet receptor antibody, aspirin, a prostaglandin inhibitor, a platelet inhibitor and a tick anti-coagulant peptide, and combinations thereof.

29. The device of claim 1, wherein the therapeutic agent is a promoter of vascular cell growth selected from the group consisting of a growth factor stimulator, a growth factor receptor agonist, a transcriptional activator, and a translational promoter, and combinations thereof.

30. The device of claim 1, wherein the therapeutic agent is an inhibitor of vascular cell growth selected from the group consisting of a growth factor inhibitor, a growth factor receptor antagonist, a transcriptional repressor, a translational repressor, an antisense DNA, an antisense RNA, a replication inhibitor, an inhibitory antibody, an antibody directed against growth factors, a bifunctional molecule consisting of a growth factor and a cytotoxin, and a bifunctional molecule consisting of an antibody and a cytotoxin, and combinations thereof.

31. The device of claim 1, wherein the therapeutic agent is selected from the group consisting of a cholesterol-lowering agent, a vasodilating agent, and agents which interfere with endogenous vasoactive mechanisms, and combinations thereof.

32. The device of claim 1, wherein the therapeutic agent is a smooth muscle inhibitor selected from the group consisting of an agent that modulates intracellular calcium binding proteins, a receptor blocker for contractile agonists, an inhibitor of the sodium/hydrogen antitransporter, a protease inhibitor, a nitrovasodilator, a phosphodiesterase inhibitor, a phenothiazine, a growth factor receptor agonist, an anti-mitotic agent, an immunosuppressive agent, and a protein kinase inhibitor, and combinations thereof.

33. The device of claim 1, wherein the therapeutic agent is a radioactive isotope.

34. The device of claim 1, wherein the radioactive isotope is selected from the group consisting of a beta particle emitting isotope and a gamma particle emitting isotope.

35. The device of claim 1, further comprising means for delivering the device to the preselected site comprised of:

a. a delivery stylet adapted to be removably disposed through the central lumen, comprised of a neck portion having a proximal tip, a distal tip and a middle portion interconnecting the neck portion and distal tip;

b. retaining means located on the middle portion for removably securing the device to the stylet; and

c. means adjacent the proximal tip for controlling the delivery of the device within the vessel at the predetermined site.

36. A removable, expandable, adapted for providiascular support device adapted for providing prolonged localized delivery of a therapeutic agent to a preselected site within a blood vessel, comprising:

a. an inflatable, elongated, tubular-shaped balloon having a proximal end, a distal end and a central lumen therethrough, comprising;

i. a medial chamber comprised of a medial exterior wall defining the central lumen and an opposite dividing wall interconnected at the proximal and distal ends, and

ii. a lateral chamber coaxially disposed about the medial chamber comprised of the dividing wall, and an opposite lateral exterior wall interconnected at the proximal and distal ends;

b. medial chamber inflation means in fluid connection with the medial chamber;

c. lateral chamber inflation means in fluid connection with the lateral chamber; and

d. therapeutic agent delivery means located on a selected one of the medial exterior wall or the lateral exterior wall.

37. The device of claim 36, wherein the therapeutic agent delivery means comprises a selected one of the medial exterior wall or the lateral exterior wall defining a plurality of micro pores disposed therethrough.

38. The device of claim 36, wherein the micro pores are located in the lateral exterior wall and are juxtaposed to a luminal surface of the blood vessel such that a substance delivered therethrough directly contacts the luminal surface of the blood vessel.

39. The device of claim 38, wherein the micro pores are located in the medial exterior wall such that a substance delivered therethrough is delivered into the boundary layer of blood flowing through the blood vessel.

40. The device of claim 36, wherein the therapeutic agent delivery means comprises a selectively permeable membrane comprising at least a portion of a selected one of the medial or lateral exterior walls.

41. The device of claim 40, wherein the selectively permeable membrane is located in the lateral exterior wall and are juxtaposed to a luminal surface of the blood vessel such that a substance delivered therethrough directly contacts the luminal surface of the blood vessel.

42. The device of claim 40, wherein the selectively permeable membrane is located in the medial exterior wall such that a substance delivered therethrough is delivered into the boundary layer of blood flowing through the blood vessel.

43. The device of claim 40, wherein the selectively permeable membrane is comprised of a biocompatible material selected from the group consisting of a biodegradable polymer, a non-biodegradable polymer, a nylon and a porous metal alloy.

44. The device of claim 43, wherein the selectively permeable membrane is a non-biodegradable polymer selected from the group consisting of polytetrafluoroethylene, ethylene vinyl acetate, polyethylene, polyethylene terephthalate, and polyurethane.

45. The device of claim 36, wherein the predetermined site is the boundary layer of blood flowing through the blood vessel upstream of a target treatment area.

46. The device of claim 36, wherein the medial chamber inflation means comprises a low profile elongated inflation fluid supply tube in fluid communication with the proximal end of the medial chamber.

47. The device of claim 36, wherein the lateral chamber inflation means comprises a low profile elongated inflation fluid supply tube in fluid communication with the proximal end of the lateral chamber.

48. The device of claim 36, further comprising means for delivering the device to the preselected site comprised of:

a. a delivery stylet adapted to be removably disposed through the central lumen, comprised of a proximal tip, a distal tip and a middle portion interconnecting the proximal and distal tips;

b. retaining means located on the middle portion for removably securing the device to the stylet; and

c. means for controlling the delivery of the device within the vessel at the predetermined site.

49. The device of claim 36, wherein the medial wall expands to a predetermined diameter in response to a preselected amount of an inflation fluid pressure applied to the medial chamber by the medial chamber inflation means.

50. The device of claim 36, wherein the dividing wall expands to a predetermined length and diameter in response to a preselected amount of an inflation fluid pressure applied to a selected one of the medial or lateral chambers by the corresponding medial or lateral chamber inflation means.

51. The device of claim 36, wherein the lateral wall expands to a predetermined length and diameter in response to a preselected amount of an inflation fluid pressure applied to the lateral chamber by the lateral chamber inflation means.

52. The device of claim 36, wherein the therapeutic agent is disposed within a fluid supplied to a selected one of said medial or lateral chambers via the medial or lateral chamber inflation means.

53. The device of claim 36, wherein the therapeutic agent is a drug.

54. The device of claim 36, wherein the therapeutic agent is an anticoagulant selected from the group consisting of D-Phe-Pro-Arg chloromethyl ketone, an RGD peptide-containing compound, heparin, an antithrombin compound, a platelet receptor antagonist, an anti-thrombin antibody, an anti-platelet receptor antibody, aspirin, a prostaglandin inhibitor, a platelet inhibitor and a tick anti-platelet peptide, and combinations thereof.

55. The device of claim 36, wherein the therapeutic agent is a promoter of vascular cell growth selected from the group consisting of a growth factor stimulator, a growth factor receptor agonist, a transcriptional activator, and a translational promoter, and combinations thereof.

56. The device of claim 36, wherein the therapeutic agent is an inhibitor of vascular cell growth selected from the group consisting of a growth factor inhibitor, a growth factor receptor antagonist, a transcriptional repressor, a translational repressor, an antisense DNA, an antisense RNA, a replication inhibitor, an inhibitory antibody, an antibody directed against growth factors, a bifunctional molecule consisting of a growth factor and a cytotoxin, and a bifunctional molecule consisting of an antibody and a cytotoxin, and combinations thereof.

57. The device of claim 36, wherein the therapeutic agent is selected from the group consisting of a cholesterol-lowering agent, a vasodilating agent, and agents which interfere with endogenous vasoactive mechanisms, and combinations thereof.

58. The device of claim 36, wherein the therapeutic agent is a smooth muscle inhibitor selected from the group consisting of an agent that modulates intracellular calcium binding proteins, a receptor blocker for contractile agonists, an inhibitor of the sodium/hydrogen antitransporter, a protease inhibitor, a nitrovasodilator, a phosphodiesterase inhibitor, a phenothiazine, a growth factor receptor agonist, an anti-mitotic agent, an immunosuppressive agent, and a protein kinase inhibitor, and combinations thereof.

59. The device of claim 36, wherein the therapeutic agent is a radioactive isotope.

60. The device of claim 36, wherein the radioactive isotope is selected from the group consisting of a beta particle emitting isotope and a gamma particle emitting isotope.

61. A removable, non-occlusive, endovascular support device adapted for prolonged localized delivery of a therapeutic agent at a preselected site within a blood vessel, comprising:

a. a tubular-shaped, dual-chambered, expandable member having a proximal end, a distal end, an exterior surface and an interior surface defining a central lumen therethrough, comprising;

i. a support chamber formed from a plurality of inflatable interconnecting inflation cells; and

ii. a tubular-shaped therapeutic agent delivery chamber interspersed between the inflation cells and having an outside surface with a medial face and a lateral face defined by the exterior and interior surfaces respectively of the tubular-shaped member;

b. support chamber inflation means in fluid connection with the support chamber;

c. a therapeutic agent delivery tube in fluid connection with the therapeutic agent delivery chamber; and

d. therapeutic agent delivery means located on a selected one of the medial or lateral surfaces of the therapeutic agent delivery chamber.

62. The device of claim 61, wherein the therapeutic agent delivery means comprises a selected one of the medial exterior wall or the lateral exterior wall defining a plurality of micro pores disposed therethrough.

63. The device of claim 61, wherein the support chamber inflation means comprises a low profile elongated inflation fluid supply tube in fluid communication with the proximal end of the support chamber.

64. The device of claim 61, further comprising means for delivering the device to the preselected site comprised of:

a. a delivery stylet adapted to be removably disposed through the central lumen, comprised of a proximal tip, a distal tip and a middle portion interconnecting the proximal and distal tips;

b. retaining means located on the middle portion for removably securing the device to the stylet; and

c. means for controlling the delivery of the device within the vessel at the predetermined site.

65. The device of claim 61, further comprising a removable delivery or deployment sheath coaxially disposed about and covering at least a portion of the device.